In this analysis, we examined the literature about HAIC and anti-PD-1 mAb combined therapy, and investigated the potential mechanisms by which HAIC may augment the effectiveness of immunotherapy in the heterogeneous and suppressive immune microenvironment of HCC. Here, PDCD1 is linked to hepatocellular carcinoma.